EXICURE, INC. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
EXICURE, INC. (XCUR) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$1.17 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-03-25
- EXICURE, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$1.17M.
- EXICURE, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$2.04M.
- EXICURE, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2023 was -$3.55M.
- EXICURE, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2022 was -$498.00K.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | -$1.17M 10-K · filed 2026-03-25 |
| 2024-12-31 | -$2.04M 10-K · filed 2026-03-25 |
| 2023-12-31 | -$3.55M 10-K · filed 2025-03-18 |
| 2022-12-31 | -$498.00K 10-K · filed 2024-06-06 |
| 2021-12-31 | -$13.46M 10-K · filed 2023-03-27 |
| 2020-12-31 | -$5.18M 10-K · filed 2022-03-25 |
| 2019-12-31 | -$5.52M 10-K · filed 2021-03-11 |
| 2018-12-31 | -$4.71M 10-K · filed 2020-03-10 |
| 2017-12-31 | -$4.09M 10-K/A · filed 2019-09-23 |
| 2016-12-31 | -$5.76M 10-K · filed 2018-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |